Genmab — November 2020

[E_L]

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies https://ashpublications.org/blood/article/132/Supplement 1/1664/273265/Duobody-CD3xCD20-Shows-Unique-and-Potent?searchresult=1

[E_L]

Immunoprofiling of Normal Human Donor Blood Identified Potential Pharmacodynamic Markers for JNJ-63709178 (CD123xCD3) Duobody Antibody Treatment https://ashpublications.org/blood/article/128/22/5215/100049/Immunoprofiling-of-Normal-Human-Donor-Blood?searchresult=1

[E_L]

forget that last one, it is old offcourse

[E_L]

i just picked 1 Dara abstract, too many to post all

[E_L]

Pattern of Use and Efficacy of Daratumumab-Based Therapy in Patients with AL Amyloidosis: A Single Institution Experience

[E_L]

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) https://ashpublications.org/blood/article/136/Supplement 1/40/470139/A-Phase-1-First-in-Human-Study-of-Talquetamab-a-G?searchresult=1

[E_L]

very interesting. had Talquetamab as a lotery ticket, early data encouriging though, even though a few grade 3 crs
?

[E_L]

MTD has not been defined and dose escalation continues, with the study nearing a RP2D.

[Bulder]

Yes, but only grade 1-2 with sc dosing. Amd it looks that they have decided for sc, as that is the chosen adm in the combination study.

[Bulder]

301 Moved Permanently

(www.clinicaltrials.gov)

[E_L]

that is a good point. the PhII is also SC https://clinicaltrials.gov/ct2/history/NCT04557098?A=1&B=2&C=merged#StudyPageTop

[E_L]

ORR was a bit higher at IV though, probably still have to jack up the SC dose a bit

[E_L]

looks good though, no?

[Bulder]

indeed, can't wait to see the outcome in combo with dara.

[Solsen]

Knock off your socks

[AaBforever]

Gen 6%...:-)

[E_L]

Genmab Announces Data to be Presented at 2020 ASH Annual Meeting https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-be-presented-2020-ash-annual-meeting

[E_L]

Subcutaneous Epcoritamab Induces Complete Responses With an Encouraging Safety Profile Across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients With Prior CAR-T Therapy: Updated Dose-Escalation Data– Oral presentation,

[E_L]

i can't find that one online yet?

[StockBull]

AbbVie +9% - kanon dag